Nektar Therapeutics (0UNL) Share Forecast & Price Target
0UNL Analyst Ratings
Moderate Buy
10Buy4Hold0Sell
Based on 14 analysts giving stock ratings to Nektar Therapeutics in the past 3 months
0UNL Stock 12 Month Forecast
Average Price Target
$132.45▲(246.47% Upside)Based on 14 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $132.45 with a high forecast of $192.00 and a low forecast of $50.00. The average price target represents a 246.47% change from the last price of $38.23.
Past 12 Months12 Month ForecastJan2026Oct2026
High$192.00
Average$132.45
Low$50.00
Highest Price TargetHighest$192.00Average Price Target$132.45Lowest Price TargetLowest$50.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Yasmeen Rahimi | Piper Sandler | $192 | buy | 402.22%Upside | Reiterated | 10/22/26 | ||
| Alice Nettleton | UBS | $53 | hold | 38.63%Upside | Initiated | 10/12/26 | ||
| Will Soghikian | Leerink Partners | $130 | buy | 240.05%Upside | Initiated | 10/12/26 | ||
| Julian Harrison | BTIG | $178 | buy | 365.60%Upside | Reiterated | 10/09/26 | ||
| Thomas Deal | Raymond James | ― | hold | ― | Initiated | 10/08/26 | ||
| Samantha Semenkow | Citi | $151 | buy | 294.98%Upside | Reiterated | 10/05/26 | ||
| Arthur He CFA | H.C. Wainwright | $185 | buy | 383.91%Upside | Reiterated | 10/02/26 | ||
 Unknown AnalystNot Ranked | B. Riley Securities | $150 | buy | 292.36%Upside | Reiterated | 10/02/26 | ||
| Andy Hsieh | William Blair | ― | buy | ― | Reiterated | 10/01/26 | ||
| Roger Song | Jefferies | $150 | buy | 292.36%Upside | Reiterated | 10/01/26 | ||
| Edward Nash | Canaccord Genuity | $153 | buy | 300.21%Upside | Reiterated | 09/28/26 | ||
| Martin Fan | Wedbush | $80→$50 | hold | 30.79%Upside | Reiterated | 09/23/26 | ||
| Jessica Fye | J.P. Morgan | $65 | hold | 70.02%Upside | Initiated | 08/21/26 | ||
| Marc Frahm | TD Cowen | ― | buy | ― | Reiterated | 08/13/26 | ||
| Jay Olson | Oppenheimer | $140 | buy | 266.20%Upside | Reiterated | 05/08/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Yasmeen Rahimi | 10/22/26 | $192 | buy | 402.22%Upside | Reiterated | Piper Sandler | ||
| Alice Nettleton | 10/12/26 | $53 | hold | 38.63%Upside | Initiated | UBS | ||
| Will Soghikian | 10/12/26 | $130 | buy | 240.05%Upside | Initiated | Leerink Partners | ||
| Julian Harrison | 10/09/26 | $178 | buy | 365.60%Upside | Reiterated | BTIG | ||
| Thomas Deal | 10/08/26 | ― | hold | ― | Initiated | Raymond James | ||
| Samantha Semenkow | 10/05/26 | $151 | buy | 294.98%Upside | Reiterated | Citi | ||
| Arthur He CFA | 10/02/26 | $185 | buy | 383.91%Upside | Reiterated | H.C. Wainwright | ||
| Unknown AnalystNot Ranked | 10/02/26 | $150 | buy | 292.36%Upside | Reiterated | B. Riley Securities | ||
| Andy Hsieh | 10/01/26 | ― | buy | ― | Reiterated | William Blair | ||
| Roger Song | 10/01/26 | $150 | buy | 292.36%Upside | Reiterated | Jefferies | ||
| Edward Nash | 09/28/26 | $153 | buy | 300.21%Upside | Reiterated | Canaccord Genuity | ||
| Martin Fan | 09/23/26 | $80→$50 | hold | 30.79%Upside | Reiterated | Wedbush | ||
| Jessica Fye | 08/21/26 | $65 | hold | 70.02%Upside | Initiated | J.P. Morgan | ||
| Marc Frahm | 08/13/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Jay Olson | 05/08/26 | $140 | buy | 266.20%Upside | Reiterated | Oppenheimer |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Nektar Therapeutics
3 Months
Success Rate8/19 ratings generated profit
42%
Average Return
+28.23%
Copying Arthur He CFA's trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of +28.23% per trade.
1 Year
Success Rate10/15 ratings generated profit
67%
Average Return
+154.50%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +154.50% per trade.
2 Years
Success Rate10/15 ratings generated profit
67%
Average Return
+60.92%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +60.92% per trade.
0UNL Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 11 | 15 | 18 | 11 |
| Buy | 2 | 2 | 2 | 3 | 1 |
| Hold | 1 | 2 | 3 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 12 | 15 | 20 | 26 | 15 |
In the current month, 0UNL has received 12 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0UNL average Analyst price target in the past 3 months is 132.45.
0UNL Financial Forecast
High$-1.71
Consensus$-2.07
Low$-3.07
0UNL Earnings Forecast
Next quarter’s earnings estimate for 0UNL is -$2.07 with a range of -$3.07 to -$1.71. The previous quarter’s EPS was -$1.23. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$11M
Consensus$10.3M
Low$9.54M
0UNL Sales Forecast
Next quarter’s sales forecast for 0UNL is $10.27M with a range of $9.54M to $11.00M. The previous quarter’s sales results were $10.13M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0UNL Stock Forecast FAQ
What is GB:0UNL’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is $132.45.
What is GB:0UNL’s upside potential, based on the analysts’ average price target?
Nektar Therapeutics has 246.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Nektar Therapeutics a Buy, Sell or Hold?
Nektar Therapeutics has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.
What is Nektar Therapeutics’s share price target?
The average share price target for Nektar Therapeutics is $132.45. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $192.00, and the lowest forecast is $50.00. The average share price target represents a 246.47% increase from the current price of $38.23.
What do analysts say about Nektar Therapeutics?
Nektar Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of Nektar Therapeutics?
To buy shares of GB:0UNL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
